Control BionicsASX:CBL -3.53% Current Ratio is 2.22 as of Dec. 2025, which is 47% below its 10-year median of 4.19. The stock has 7 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Control Bionics ranks worse than 56.91% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Control Bionics's current ratio for the quarter that ended in Dec. 2025 was 2.22.
Control Bionics has a current ratio of 2.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for Control Bionics's Current Ratio or its related term are showing as below:
ASX:CBL'
s Current Ratio Range Over the Past 10 Years
Min: 1.24 Med: 4.19 Max: 44.21
Current: 2.22
During the past 6 years, Control Bionics's highest Current Ratio was 44.21. The lowest was 1.24. And the median was 4.19.
ASX:CBL's Current Ratio is ranked worse than 56.91% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs ASX:CBL: 2.22
Control Bionics (ASX:CBL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Control Bionics Current Ratio Related Terms
Control Bionics Current Ratio Historical Data
* Premium members only.
The historical data trend for Control Bionics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Control Bionics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Control Bionics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Current Ratio of 2.22 as of Dec. 2025. This is 47% below median its historical median of 4.19. Over the past decade, Control Bionics' Current Ratio has ranged from 1.24 to 44.21. According to the industry distribution chart, Control Bionics ranks #486 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 56.9%.
Is Control Bionics' Current Ratio too high?
Control Bionics' current Current Ratio of 2.22 is 47% below median its 10-year median of 4.19. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 44.21. The Medical Devices & Instruments industry median Current Ratio is 2.49. Control Bionics' value of 2.22 is 10.7% below this industry median. Based on the distribution chart, Control Bionics ranks #486 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Control Bionics' Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #486 out of 854 companies for Current Ratio. This places Control Bionics in the lower half of its industry. The industry median Current Ratio is 2.49. Control Bionics' value of 2.22 is 10.7% below this benchmark. Historically, Control Bionics' own Current Ratio has ranged from 1.24 to 44.21 over the past decade. While the company's 10-year median is 4.19 vs. the industry median of 2.49, Control Bionics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Current Ratio of 2.22 is 10.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Current Ratio is 2.22, which is 47% below median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.08 — trading 173.3% above its estimated fair value. The current Current Ratio is 2.22, which is 47% below median its 10-year median of 4.19 and 10.7% below the Medical Devices & Instruments industry median of 2.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Current Ratio is 2.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 